Evidence map›Paper›PMID 42818285›Full record

ArticlebioRxiv : the preprint server for biology2026

Targeting fibroblast activation suppresses chemotherapy-induced pro-invasive remodeling of the extracellular matrix.

Anna Yui, Liyi Peng, Katie C Lew, Dylan J Landau, Crystal Zhang, Thomas J Gerton, Marissa Li, Steffy Jullian Guyard, Mallory M Caron, Jackson P Fatherree and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Anna YuiDepartment of Biomedical Engineering, School of Engineering, Tufts University, Medford, MA 02155, USA.
Liyi PengDepartment of Biomedical Engineering, School of Engineering, Tufts University, Medford, MA 02155, USA.
Katie C LewDepartment of Biomedical Engineering, School of Engineering, Tufts University, Medford, MA 02155, USA.
Dylan J LandauDepartment of Biomedical Engineering, School of Engineering, Tufts University, Medford, MA 02155, USA.
Crystal ZhangDepartment of Biomedical Engineering, School of Engineering, Tufts University, Medford, MA 02155, USA.
Thomas J GertonDepartment of Biomedical Engineering, School of Engineering, Tufts University, Medford, MA 02155, USA.
Marissa LiTufts University School of Medicine, Boston, MA 02111, USA.
Steffy Jullian GuyardDepartment of Biomedical Engineering, School of Engineering, Tufts University, Medford, MA 02155, USA.
Mallory M CaronDepartment of Biomedical Engineering, School of Engineering, Tufts University, Medford, MA 02155, USA.
Jackson P FatherreeDepartment of Biomedical Engineering, School of Engineering, Tufts University, Medford, MA 02155, USA.
Rachel A McGinnDepartment of Biomedical Engineering, School of Engineering, Tufts University, Medford, MA 02155, USA.
Abraham L BayerDepartment of Immunology, Tufts University School of Medicine, Boston, MA 02111, USA.ORCID 0000-0001-7534-6354
Pilar AlcaideDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.ORCID 0000-0003-3013-3982
Charlotte KuperwasserDepartment of Developmental, Molecular & Chemical Biology, Tufts University School of Medicine, Boston, MA 02111, USA.ORCID 0000-0001-7913-9619
Madeleine J OudinDepartment of Biomedical Engineering, School of Engineering, Tufts University, Medford, MA 02155, USA.ORCID 0000-0001-6988-4260

Funding

Mechanisms of T cell activation in cardiac fibrosis and non-ischemic heart failureR01HL144477 · NHLBI · TUFTS UNIVERSITY BOSTON · PI ALCAIDE ALONSO, MARIA PILAR · 2019 to 2023
$3.2M
Regulation of T cell immune response in Heart Failure with Preserved Ejection FractionR01HL165725 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Maria Pilar Alcaide Alonso · 2023 to 2026
$2.5M
Defining and Exploiting the Neuronal Identity of CancersDP2CA271387 · NCI · TUFTS UNIVERSITY MEDFORD · PI OUDIN, MADELEINE JULIE · 2021 to 2024
$2.3M
Investigating mechanisms of chemoresistance in triple-negative breast cancerR01CA255742 · NCI · TUFTS UNIVERSITY MEDFORD · PI Madeleine Julie Oudin · 2022 to 2026
$1.8M
Comparing the role of MyD88 and TRIF in T-cell effector function and the development of heart failureF30HL162200 · NHLBI · TUFTS UNIVERSITY BOSTON · PI Abraham Bayer · 2022 to 2026
$238k
NCI NIH HHS DP2 CA271387NCI NIH HHS R01 CA255742NHLBI NIH HHS F30 HL162200NHLBI NIH HHS R01 HL144477NHLBI NIH HHS R01 HL165725
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that accounts for nearly 20% of breast cancer diagnoses. Despite recent approvals of novel therapeutic agents for TNBC, neoadjuvant chemotherapy remains part of standard of care treatment for TNBC patients. However, approximately 60% of TNBC patients who received neoadjuvant chemotherapy fail to achieve pathological complete response and face significantly elevated risks of recurrence and distant metastasis. We have shown that chemotherapy can induce significant changes in TNBC tumor extracellular matrix (ECM) that drive tumor cell invasion and may contribute to recurrence. Here, we investigate how chemotherapy drugs can impact resident fibroblasts, the major generators of ECM in the breast tissue. We find that chemotherapy activates fibroblasts and that doxorubicin specifically induces the production of pro-invasive ECM by fibroblasts via TGF-β/Smad3 signaling. An FDA-approved tyrosine kinase inhibitor nintedanib suppressed doxorubicin-induced fibroblast activation and pro-invasive ECM production by fibroblasts

Identifiers

PMID42818285
PMCPMC13622556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.